Digoxin therapy: A persisting interest despite contrary winds

ABC of monitoring drug therapy. Digoxin.

The plasma digoxin concentration that will result from a given dose of the drug can be predicted at best with only 34% accuracy, although knowledge of a previous concentration improves the ability to predict subsequent concentrations. In outpatients taking a fixed daily dosage, a steady state plasma digoxin concentrations vary widely (between 0 5 and 3 5 nmol/l). This means that if a target pla...

Digoxin therapy for heart failure: an update.

Digoxin therapy has long been used to treat heart failure; however, its effectiveness was not completely known until recently. Results of the Digitalis Investigation Group trial showed that adding digoxin to standard heart failure therapy had no effect on mortality. However, adding digoxin decreased hospitalizations related to heart failure and improved symptoms in patients treated for heart fa...

Pentosan polysulfate prevents glomerular hypertension and structural injury despite persisting hypertension in 5/6 nephrectomy rats.

Five/six nephrectomy induces systemic and glomerular hypertension, glomerulosclerosis, proteinuria, and tubulointerstitial fibrosis. Polysulfate pentosan (PPS) decreases mesangial proliferation and extracellular matrix accumulation. The aim of this study was to determine whether PPS prevents glomerular hemodynamic changes and renal damage. Micropuncture studies were performed in three groups of...

good outcome after digoxin toxicity despite very high serum potassium level

Rapid clinical improvement of peripheral artery occlusive disease symptoms after nilotinib discontinuation despite persisting vascular occlusion

Peripheral artery occlusive disease (PAOD) is an emerging adverse event in chronic myelogenous leukemia (CML) patients treated with nilotinib. The largest published cohort of CML patients treated with nilotinib comes from the phase III ENESTnd trial (Evaluating Nilotinib Efficacy and Safety in Clinical Trials newly diagnosed patients), which compared nilotinib (300 or 400mg BID) to standard the...